Legend Biotech (LEGN) Stock: Buy, Sell, or Hold?
LEGN - Legend Biotech Corporation American Depositary Shares
$18.90
0.27 (1.45%)
â˛
5d:
-4.55%
30d:
+2.44%
90d:
-14.94%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When LEGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LEGN is fairly priced but lacks strong directional signals. At -4.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LEGN is fairly priced but lacks strong directional signals. At -4.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.93
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.86
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LEGN is currently trading at $18.90, which is considered fair relative to its 30-day fair value range of $17.97 to $19.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 27.7) compared to its historical average (32.0). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, LEGN is in a strong downtrend. Immediate support is located at $17.56, while resistance sits at $19.92.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.62 (+141.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEGN is in a strong downtrend. Immediate support is located at $17.56, while resistance sits at $19.92.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.62 (+141.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.97 -
$19.23
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 141.4% below Wall St target ($45.62)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.97 -
$19.23
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.56
Resistance Level
$19.92
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.67
Wall Street Target
$45.62
(+141.4%)
Revenue Growth (YoY)
51.9%
Profit Margin
-7.2%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
27.7 vs 32.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$17.99
(-5%)
2-Year Target
$17.13
(-9%)
3-Year Target
$16.31
(-14%)
3-Yr Target (if PE normalizes)
(PE: 28â32)
$18.86
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.7 to 32.0
Stabilization Target:
$21.86
(+15.7%)
PE Expansion Potential:
+15.7%
Share & Embed Analysis
Last updated: October 23, 2026 4:07 AM ET
Data refreshes hourly during market hours. Next update: 5:07 AM
Data refreshes hourly during market hours. Next update: 5:07 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
